{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:53Z","timestamp":1791918953573,"version":"4.3.4"},"reference-count":168,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neurodegenerative disorders, including Alzheimer\u2019s disease (AD), are a growing problem in aging society. The amyloid cascade hypothesis has recently been questioned, and therapies based on it have not yielded the expected results. However, the role of amyloid-\u03b2 (A\u03b2) in AD pathogenesis cannot be rejected. It appears that some of the key players in the pathogenesis of the disease are the soluble amyloid-\u03b2 oligomers. Soluble amyloid-\u03b2 oligomers have neurotoxic effects by disrupting intracellular Ca2+ homeostasis and impairing mitochondrial function. The glymphatic system is an important pathway for the removal of soluble amyloid forms from the brain. The decline in the activity of this system is observed in aging brains, which is correlated with the occurrence of Alzheimer\u2019s disease, primarily among the elderly population. Therefore, the question arises as to whether the glymphatic system could be another potential target for therapeutic interventions in Alzheimer\u2019s disease. In this regard, it is imperative to pay attention to the factors that contribute to the pathogenesis of Alzheimer\u2019s disease and also impact the glymphatic system, such as sleep, physical activity, alcohol consumption, and supplementation with polyunsaturated fatty acids. The question remains whether the glymphatic system will become the key to treating Alzheimer\u2019s disease.<\/jats:p>","DOI":"10.3390\/ijms26157552","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T07:45:11Z","timestamp":1754466311000},"page":"7552","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Therapeutic Potential of Glymphatic System Activity to Reduce the Pathogenic Accumulation of Cytotoxic Proteins in Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3898-5775","authenticated-orcid":false,"given":"Kamila","family":"Kope\u0107","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw, \u017bwirki i Wigury 61, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Koziorowski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw, \u017bwirki i Wigury 61, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-5901","authenticated-orcid":false,"given":"Stanis\u0142aw","family":"Szlufik","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw, \u017bwirki i Wigury 61, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Santiago, J.A., and Potashkin, J.A. (2021). The Impact of Disease Comorbidities in Alzheimer\u2019s Disease. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.631770"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., and Yang, J. (2019). New Insights Into the Pathogenesis of Alzheimer\u2019s Disease. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.01312"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/DDDT.S130514","article-title":"Proteinopathy, oxidative stress and mitochondrial dysfunction: Cross talk in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"11","author":"Ganguly","year":"2017","journal-title":"Drug. Des. Devel. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/archneur.59.11.1764","article-title":"Survival following a diagnosis of Alzheimer disease","volume":"59","author":"Brookmeyer","year":"2002","journal-title":"Arch. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2648.2007.04494.x","article-title":"Quality of life for caregivers of people with Alzheimer\u2019s disease","volume":"61","author":"Vellone","year":"2008","journal-title":"J. Adv. Nurs."},{"key":"ref_6","first-page":"125","article-title":"Clinical features and multidisciplinary approaches to dementia care","volume":"4","author":"Grand","year":"2011","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"(2023). 2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement., 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.nrl.2016.02.016","article-title":"Prevalence and incidence of Alzheimer\u2019s disease in Europe: A meta-analysis","volume":"32","author":"Niu","year":"2017","journal-title":"Neurologia"},{"key":"ref_9","first-page":"21","article-title":"Relative roles of plaques and tangles in the dementia of Alzheimer\u2019s disease: Correlations using three sets of neuropathological criteria","volume":"6","author":"Nagy","year":"1995","journal-title":"Dementia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","article-title":"Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease","volume":"45","author":"Price","year":"1999","journal-title":"Ann. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1749-6632.1996.tb34410.x","article-title":"Tau protein and the neurofibrillary pathology of Alzheimer\u2019s disease","volume":"777","author":"Goedert","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/jclinpath-2019-205952","article-title":"Molecular pathology of neurodegenerative diseases: Principles and practice","volume":"72","author":"Kovacs","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JAD-2009-0960","article-title":"Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: Relationship and links in Alzheimer\u2019s disease","volume":"16","author":"Huang","year":"2009","journal-title":"J. Alzheimers. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369101","article-title":"Amyloid-beta: A crucial factor in Alzheimer\u2019s disease","volume":"24","author":"Sabermarouf","year":"2015","journal-title":"Med. Princ. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrn.2017.29","article-title":"Not just amyloid: Physiological functions of the amyloid precursor protein family","volume":"18","author":"Muller","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","article-title":"An overview of APP processing enzymes and products","volume":"12","author":"Chow","year":"2010","journal-title":"Neuromolecular Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Tolar, M., Hey, J., Power, A., and Abushakra, S. (2021). Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer\u2019s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126355"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1523\/JNEUROSCI.05-10-02801.1985","article-title":"Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer\u2019s disease","volume":"5","author":"Rogers","year":"1985","journal-title":"J. Neurosci."},{"key":"ref_20","first-page":"293","article-title":"Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer\u2019s disease?","volume":"62","author":"Permanne","year":"2002","journal-title":"J. Neural Transm."},{"key":"ref_21","first-page":"1359","article-title":"Profile of gantenerumab and its potential in the treatment of Alzheimer\u2019s disease","volume":"7","author":"Novakovic","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1093\/brain\/awad159","article-title":"The amyloid cascade hypothesis: An updated critical review","volume":"146","author":"Kepp","year":"2023","journal-title":"Brain"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nn.4017","article-title":"The case for rejecting the amyloid cascade hypothesis","volume":"18","author":"Herrup","year":"2015","journal-title":"Nat. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","article-title":"The Amyloid Cascade Hypothesis in Alzheimer\u2019s Disease: It\u2019s Time to Change Our Mind","volume":"15","author":"Ricciarelli","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101996","DOI":"10.1016\/j.arr.2023.101996","article-title":"Passive Alzheimer\u2019s immunotherapy: A promising or uncertain option?","volume":"90","author":"Revheim","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wojtunik-Kulesza, K., Rudkowska, M., and Orze\u0142-Sajd\u0142owska, A. (2023). Aducanumab\u2014Hope or Disappointment for Alzheimer\u2019s Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054367"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/brain\/awx059","article-title":"Alzheimer\u2019s disease: Where next for anti-amyloid therapies?","volume":"140","author":"Hardy","year":"2017","journal-title":"Brain"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tampi, R.R., Forester, B.P., and Agronin, M. (2021). Aducanumab: Evidence from clinical trial data and controversies. Drugs Context, 10.","DOI":"10.7573\/dic.2021-7-3"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Fedele, E. (2023). Anti-Amyloid Therapies for Alzheimer\u2019s Disease and the Amyloid Cascade Hypothesis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914499"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/d41573-024-00116-1","article-title":"FDA approves third anti-amyloid antibody for Alzheimer disease","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e12112","DOI":"10.1002\/trc2.12112","article-title":"Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease","volume":"7","author":"Lowe","year":"2021","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer\u2019s Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Espay, A.J., Kepp, K.P., and Herrup, K. (2024). Lecanemab and Donanemab as Therapies for Alzheimer\u2019s Disease: An Illustrated Perspective on the Data. eNeuro, 11.","DOI":"10.1523\/ENEURO.0319-23.2024"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated Brain Volume Loss Caused by Anti-beta-Amyloid Drugs: A Systematic Review and Meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e12377","DOI":"10.1002\/trc2.12377","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1212\/WNL.0000000000006926","article-title":"Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases","volume":"92","author":"Espay","year":"2019","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3940(90)90391-L","article-title":"Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person","volume":"116","author":"Delaere","year":"1990","journal-title":"Neurosci. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1212\/WNL.56.12.1690","article-title":"Prevalence of Alzheimer\u2019s disease in very elderly people: A prospective neuropathological study","volume":"56","author":"Polvikoski","year":"2001","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1212\/01.wnl.0000343853.00346.a4","article-title":"APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old","volume":"72","author":"Berlau","year":"2009","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid beta oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhang, H., Jiang, X., Ma, L., Wei, W., Li, Z., Chang, S., Wen, J., Sun, J., and Li, H. (2022). Role of Abeta in Alzheimer\u2019s-related synaptic dysfunction. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.964075"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1039\/C6CS00731G","article-title":"Towards an understanding of amyloid-beta oligomers: Characterization, toxicity mechanisms, and inhibitors","volume":"46","author":"Lee","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1750-1326-9-48","article-title":"Oligomeric Abeta-induced synaptic dysfunction in Alzheimer\u2019s disease","volume":"9","author":"Tu","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1074\/jbc.M116.762526","article-title":"Ion Channel Formation by Amyloid-beta42 Oligomers but Not Amyloid-beta40 in Cellular Membranes","volume":"292","author":"Bode","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"McDaid, J., Mustaly-Kalimi, S., and Stutzmann, G.E. (2020). Ca2+ Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer\u2019s Disease. Cells, 9.","DOI":"10.3390\/cells9122655"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.32607\/20758251-2010-2-1-72-80","article-title":"Calcium signaling and neurodegeneration","volume":"2","author":"Bezprozvanny","year":"2010","journal-title":"Acta Naturae"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ferreira, A. (2012). Calpain dysregulation in Alzheimer\u2019s disease. ISRN Biochem., 2012.","DOI":"10.5402\/2012\/728571"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bukke, V.N., Archana, M., Villani, R., Romano, A.D., Wawrzyniak, A., Balawender, K., Orkisz, S., Beggiato, S., Serviddio, G., and Cassano, T. (2020). The Dual Role of Glutamatergic Neurotransmission in Alzheimer\u2019s Disease: From Pathophysiology to Pharmacotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207452"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1007S","DOI":"10.1093\/jn\/130.4.1007S","article-title":"Glutamate as a neurotransmitter in the brain: Review of physiology and pathology","volume":"130","author":"Meldrum","year":"2000","journal-title":"J. Nutr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1476-5381.2012.02057.x","article-title":"Alzheimer\u2019s disease, beta-amyloid, glutamate, NMDA receptors and memantine--searching for the connections","volume":"167","author":"Danysz","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2174\/156720511796391917","article-title":"Abeta oligomers induce glutamate release from hippocampal neurons","volume":"8","author":"Bomfim","year":"2011","journal-title":"Curr. Alzheimer. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.neuron.2009.05.012","article-title":"Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake","volume":"62","author":"Li","year":"2009","journal-title":"Neuron"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1523\/JNEUROSCI.0203-11.2011","article-title":"Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors","volume":"31","author":"Li","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hipo.23213","article-title":"The history of long-term potentiation as a memory mechanism: Controversies, confirmation, and some lessons to remember","volume":"30","author":"Dringenberg","year":"2020","journal-title":"Hippocampus"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2174\/1567205016666191023104036","article-title":"Amyloid-beta Oligomers-Induced Mitochondrial DNA Repair Impairment Contributes to Altered Human Neural Stem Cell Differentiation","volume":"16","author":"Lu","year":"2019","journal-title":"Curr. Alzheimer. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13041-016-0261-z","article-title":"Amyloid beta oligomers elicit mitochondrial transport defects and fragmentation in a time-dependent and pathway-specific manner","volume":"9","author":"Rui","year":"2016","journal-title":"Mol. Brain"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.bpj.2014.07.074","article-title":"Beta-amyloid oligomers activate apoptotic BAK pore for cytochrome c release","volume":"107","author":"Kim","year":"2014","journal-title":"Biophys. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bachiller, S., Jimenez-Ferrer, I., Paulus, A., Yang, Y., Swanberg, M., Deierborg, T., and Boza-Serrano, A. (2018). Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response. Front. Cell Neurosci., 12.","DOI":"10.3389\/fncel.2018.00488"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5150678","DOI":"10.1155\/2017\/5150678","article-title":"The Role of Microglia and Macrophages in CNS Homeostasis, Autoimmunity, and Cancer","volume":"2017","author":"Yin","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","article-title":"Microglia in Alzheimer\u2019s disease","volume":"217","author":"Hansen","year":"2018","journal-title":"J. Cell Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainresbull.2011.10.004","article-title":"Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases","volume":"87","author":"Smith","year":"2012","journal-title":"Brain Res. Bull."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Balducci, C., and Forloni, G. (2019). Doxycycline for Alzheimer\u2019s Disease: Fighting beta-Amyloid Oligomers and Neuroinflammation. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00738"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1471-4159.2010.06783.x","article-title":"Microglial activation depends on beta-amyloid conformation: Role of the formylpeptide receptor 2","volume":"114","author":"Heurtaux","year":"2010","journal-title":"J. Neurochem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2009.02.003","article-title":"Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta","volume":"210","author":"Michelucci","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40478-022-01332-9","article-title":"Abeta oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer\u2019s disease","volume":"10","author":"Salvadores","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e975","DOI":"10.1038\/cddis.2013.503","article-title":"Oligomeric amyloid beta induces IL-1beta processing via production of ROS: Implication in Alzheimer\u2019s disease","volume":"4","author":"Parajuli","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41232-018-0085-6","article-title":"Amyloid beta directly interacts with NLRP3 to initiate inflammasome activation: Identification of an intrinsic NLRP3 ligand in a cell-free system","volume":"38","author":"Nakanishi","year":"2018","journal-title":"Inflamm. Regen."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.2174\/1567205013666160401115127","article-title":"Alzheimer\u2019s Disease Genetic Risk Factor APOE-epsilon4 Also Affects Normal Brain Function","volume":"13","author":"Heinsinger","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1096\/fj.10-175976","article-title":"High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer\u2019s disease","volume":"25","author":"Cerf","year":"2011","journal-title":"FASEB J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1152\/physrev.00024.2003","article-title":"Role of tau protein in both physiological and pathological conditions","volume":"84","author":"Avila","year":"2004","journal-title":"Physiol. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-beta and tau: The trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.7150\/ijbs.57078","article-title":"Interaction between Abeta and Tau in the Pathogenesis of Alzheimer\u2019s Disease","volume":"17","author":"Zhang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer\u2019s disease Neurons","volume":"57","author":"Rajmohan","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1073\/pnas.092136199","article-title":"Tau is essential to beta -amyloid-induced neurotoxicity","volume":"99","author":"Rapoport","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer\u2019s disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaneurol.2013.1453","article-title":"Mechanisms of protein seeding in neurodegenerative diseases","volume":"70","author":"Walker","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1126\/science.1222951","article-title":"Cell biology. A unifying role for prions in neurodegenerative diseases","volume":"336","author":"Prusiner","year":"2012","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"147ra111","DOI":"10.1126\/scitranslmed.3003748","article-title":"A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta","volume":"4","author":"Iliff","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_86","first-page":"2058460115609635","article-title":"MRI with intrathecal MRI gadolinium contrast medium administration: A possible method to assess glymphatic function in human brain","volume":"4","author":"Eide","year":"2015","journal-title":"Acta Radiol. Open"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s11604-022-01275-0","article-title":"Diffusion-weighted image analysis along the perivascular space (DWI-ALPS) for evaluating interstitial fluid status: Age dependence in normal subjects","volume":"40","author":"Taoka","year":"2022","journal-title":"Jpn. J. Radiol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Eide, P.K., Vatnehol, S.A.S., Emblem, K.E., and Ringstad, G. (2018). Magnetic resonance imaging provides evidence of glymphatic drainage from human brain to cervical lymph nodes. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-25666-4"},{"key":"ref_89","first-page":"648","article-title":"Measuring Glymphatic Flow in Man Using Quantitative Contrast-Enhanced MRI","volume":"40","author":"Watts","year":"2019","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s11064-015-1581-6","article-title":"The Glymphatic System: A Beginner\u2019s Guide","volume":"40","author":"Jessen","year":"2015","journal-title":"Neurochem. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S1474-4422(18)30318-1","article-title":"The glymphatic pathway in neurological disorders","volume":"17","author":"Rasmussen","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s42466-021-00102-7","article-title":"Glymphatic system, AQP4, and their implications in Alzheimer\u2019s disease","volume":"3","author":"Silva","year":"2021","journal-title":"Neurol. Res. Pract."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Mogensen, F.L.-H., Delle, C., and Nedergaard, M. (2021). The Glymphatic System (En)during Inflammation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147491"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/physrev.00031.2020","article-title":"Fluid transport in the brain","volume":"102","author":"Rasmussen","year":"2022","journal-title":"Physiol. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.nbd.2016.05.015","article-title":"Suppression of glymphatic fluid transport in a mouse model of Alzheimer\u2019s disease","volume":"93","author":"Peng","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Gao, Y., Liu, K., and Zhu, J. (2023). Glymphatic system: An emerging therapeutic approach for neurological disorders. Front. Mol. Neurosci., 16.","DOI":"10.3389\/fnmol.2023.1138769"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13024-015-0056-1","article-title":"Deletion of aquaporin-4 in APP\/PS1 mice exacerbates brain Abeta accumulation and memory deficits","volume":"10","author":"Xu","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.26516","article-title":"Magnetic Resonance Images Implicate That Glymphatic Alterations Mediate Cognitive Dysfunction in Alzheimer Disease","volume":"93","author":"Hsu","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/acn3.81","article-title":"Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer\u2019s disease","volume":"1","author":"Mattsson","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e2648","DOI":"10.1212\/WNL.0000000000201300","article-title":"Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease","volume":"99","author":"Kamagata","year":"2022","journal-title":"Neurology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1126\/science.1180962","article-title":"Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle","volume":"326","author":"Kang","year":"2009","journal-title":"Science"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jamaneurol.2016.4202","article-title":"Associations Between beta-Amyloid Kinetics and the beta-Amyloid Diurnal Pattern in the Central Nervous System","volume":"74","author":"Lucey","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.biopsych.2017.11.031","article-title":"The Emerging Relationship Between Interstitial Fluid-Cerebrospinal Fluid Exchange, Amyloid-beta, and Sleep","volume":"83","author":"Boespflug","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"150ra122","DOI":"10.1126\/scitranslmed.3004291","article-title":"Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer\u2019s disease pathology","volume":"4","author":"Roh","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41398-018-0094-x","article-title":"Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Abeta-amyloid burden","volume":"8","author":"Mazzucchelli","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2020.06.007","article-title":"Aquaporin-4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimer\u2019s disease spectrum","volume":"97","author":"Chandra","year":"2021","journal-title":"Neurobiol. Aging"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neubiorev.2018.03.028","article-title":"Interaction between blood-brain barrier and glymphatic system in solute clearance","volume":"90","author":"Verheggen","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","article-title":"Clearance systems in the brain-implications for Alzheimer disease","volume":"11","author":"Carare","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/brain\/awaa179","article-title":"Impaired glymphatic function and clearance of tau in an Alzheimer\u2019s disease model","volume":"143","author":"Harrison","year":"2020","journal-title":"Brain"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e20211275","DOI":"10.1084\/jem.20211275","article-title":"Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration","volume":"219","author":"Ishida","year":"2022","journal-title":"J. Exp. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ana.24271","article-title":"Impairment of paravascular clearance pathways in the aging brain","volume":"76","author":"Kress","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Han, G., Zhou, Y., Zhang, K., Jiao, B., Hu, J., Zhang, Y., Wang, Z., Lou, M., and Bai, R. (2023). Age- and time-of-day dependence of glymphatic function in the human brain measured via two diffusion MRI methods. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1173221"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/jamaneurol.2016.4370","article-title":"Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains","volume":"74","author":"Zeppenfeld","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"He, X.F., Liu, D.X., Zhang, Q., Liang, F.Y., Dai, G.Y., Zeng, J.S., Pei, Z., Xu, G.Q., and Lan, Y. (2017). Voluntary Exercise Promotes Glymphatic Clearance of Amyloid Beta and Reduces the Activation of Astrocytes and Microglia in Aged Mice. Front. Mol. Neurosci., 10.","DOI":"10.3389\/fnmol.2017.00144"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1073\/pnas.1721694115","article-title":"beta-Amyloid accumulation in the human brain after one night of sleep deprivation","volume":"115","author":"Wang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Reddy, O.C., and van der Werf, Y.D. (2020). The Sleeping Brain: Harnessing the Power of the Glymphatic System through Lifestyle Choices. Brain Sci., 10.","DOI":"10.3390\/brainsci10110868"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsmc.2017.09.001","article-title":"Sleep in Normal Aging","volume":"13","author":"Li","year":"2018","journal-title":"Sleep Med. Clin."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"eaav5447","DOI":"10.1126\/sciadv.aav5447","article-title":"Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia","volume":"5","author":"Hablitz","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1388-2457(00)00542-3","article-title":"Age-dependent changes in sleep EEG topography","volume":"112","author":"Landolt","year":"2001","journal-title":"Clin. Neurophysiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.abb8739","article-title":"Glymphatic failure as a final common pathway to dementia","volume":"370","author":"Nedergaard","year":"2020","journal-title":"Science"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Gordon, N.P., Yao, J.H., Brickner, L.A., and Lo, J.C. (2022). Prevalence of sleep-related problems and risks in a community-dwelling older adult population: A cross-sectional survey-based study. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-14443-8"},{"key":"ref_122","first-page":"490","article-title":"Sleep in the Elderly","volume":"117","author":"Tatineny","year":"2020","journal-title":"Mo. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jsmc.2016.10.008","article-title":"Sleep in the Aging Population","volume":"12","author":"Miner","year":"2017","journal-title":"Sleep Med. Clin."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/00023210-200115100-00004","article-title":"Sleep disturbances in patients with Alzheimer\u2019s disease: Epidemiology, pathophysiology and treatment","volume":"15","author":"Vitiello","year":"2001","journal-title":"CNS Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/s-0037-1604351","article-title":"Sleep Disturbance, Cognitive Decline, and Dementia: A Review","volume":"37","author":"Wennberg","year":"2017","journal-title":"Semin. Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2869.1995.tb00145.x","article-title":"Symposium: Cognitive processes and sleep disturbances: Sleep\/wake patterns in Alzheimer\u2019s disease: Relationships with cognition and function","volume":"4","author":"Moe","year":"1995","journal-title":"J. Sleep Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000434629","article-title":"Sleep and Cognitive Decline: A Strong Bidirectional Relationship. It Is Time for Specific Recommendations on Routine Assessment and the Management of Sleep Disorders in Patients with Mild Cognitive Impairment and Dementia","volume":"74","author":"Guarnieri","year":"2015","journal-title":"Eur. Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.4103\/1673-5374.308071","article-title":"Sleep disorders in Alzheimer\u2019s disease: The predictive roles and potential mechanisms","volume":"16","author":"Kuang","year":"2021","journal-title":"Neural Regen. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"M131","DOI":"10.1093\/geronj\/45.4.M131","article-title":"Sleep disturbances in patients with mild-stage Alzheimer\u2019s disease","volume":"45","author":"Vitiello","year":"1990","journal-title":"J. Gerontol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"101594","DOI":"10.1016\/j.smim.2022.101594","article-title":"APOE mediated neuroinflammation and neurodegeneration in Alzheimer\u2019s disease","volume":"59","author":"Parhizkar","year":"2022","journal-title":"Semin. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"114702","DOI":"10.1016\/j.expneurol.2024.114702","article-title":"Repetitive head trauma and apoE4 induce chronic cerebrovascular alterations that impair tau elimination from the brain","volume":"374","author":"Eisenbaum","year":"2024","journal-title":"Exp. Neurol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","article-title":"Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance","volume":"3","author":"Castellano","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/jcbfm.2014.172","article-title":"Human apolipoprotein E varepsilon4 expression impairs cerebral vascularization and blood-brain barrier function in mice","volume":"35","author":"Alata","year":"2015","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"eaaw3210","DOI":"10.1126\/scitranslmed.aaw3210","article-title":"An ocular glymphatic clearance system removes beta-amyloid from the rodent eye","volume":"12","author":"Wang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000047976","article-title":"High occurrence rate of glaucoma among patients with Alzheimer\u2019s disease","volume":"47","author":"Bayer","year":"2002","journal-title":"Eur. Neurol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"s1140","DOI":"10.2741\/1172","article-title":"Glaucoma: Ocular Alzheimer\u2019s disease?","volume":"8","author":"McKinnon","year":"2003","journal-title":"Front. Biosci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/s41433-020-0836-x","article-title":"Neurodegeneration in Alzheimer\u2019s disease and glaucoma: Overlaps and missing links","volume":"34","author":"Sen","year":"2020","journal-title":"Eye"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Gedek, A., Koziorowski, D., and Szlufik, S. (2023). Assessment of factors influencing glymphatic activity and implications for clinical medicine. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1232304"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0033291708003681","article-title":"Physical activity and risk of neurodegenerative disease: A systematic review of prospective evidence","volume":"39","author":"Hamer","year":"2009","journal-title":"Psychol. Med."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Meng, Q., Lin, M.S., and Tzeng, I.S. (2020). Relationship Between Exercise and Alzheimer\u2019s Disease: A Narrative Literature Review. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.00131"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mehy.2018.07.016","article-title":"Astroglial water channel aquaporin 4-mediated glymphatic clearance function: A determined factor for time-sensitive treatment of aerobic exercise in patients with Alzheimer\u2019s disease","volume":"119","author":"Yin","year":"2018","journal-title":"Med. Hypotheses"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Chandrashekar, D.V., Steinberg, R.A., Han, D., and Sumbria, R.K. (2023). Alcohol as a Modifiable Risk Factor for Alzheimer\u2019s Disease\u2014Evidence from Experimental Studies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119492"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Lundgaard, I., Wang, W., Eberhardt, A., Vinitsky, H.S., Reeves, B.C., Peng, S., Lou, N., Hussain, R., and Nedergaard, M. (2018). Beneficial effects of low alcohol exposure, but adverse effects of high alcohol intake on glymphatic function. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-20424-y"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/ggi.14357","article-title":"Alcohol consumption and risk of Alzheimer\u2019s disease: A dose-response meta-analysis","volume":"22","author":"Xie","year":"2022","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10654-017-0225-3","article-title":"Alcohol consumption and dementia risk: A dose-response meta-analysis of prospective studies","volume":"32","author":"Xu","year":"2017","journal-title":"Eur. J. Epidemiol."},{"key":"ref_146","first-page":"299","article-title":"Alcohol use and the risk of developing Alzheimer\u2019s disease","volume":"25","author":"Tyas","year":"2001","journal-title":"Alcohol. Res. Health"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0453-0","article-title":"Alcohol use and dementia: A systematic scoping review","volume":"11","author":"Rehm","year":"2019","journal-title":"Alzheimers. Res. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/1028415X.2017.1321813","article-title":"Omega-3 fatty acids\u2019 supplementation in Alzheimer\u2019s disease: A systematic review","volume":"21","author":"Canhada","year":"2018","journal-title":"Nutr. Neurosci."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Bo, Y., Zhang, X., Wang, Y., You, J., Cui, H., Zhu, Y., Pang, W., Liu, W., Jiang, Y., and Lu, Q. (2017). The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial. Nutrients, 9.","DOI":"10.3390\/nu9010054"},{"key":"ref_150","first-page":"140","article-title":"Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: A complex association","volume":"5","author":"Fotuhi","year":"2009","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2014.11.008","article-title":"Omega-3 fatty acids intake and risks of dementia and Alzheimer\u2019s disease: A meta-analysis","volume":"48","author":"Wu","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/ene.15160","article-title":"A gene-environment interplay between omega-3 supplementation and APOE epsilon4 provides insights for Alzheimer\u2019s disease precise prevention amongst high-genetic-risk population","volume":"29","author":"Li","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1096\/fj.201600896","article-title":"Omega-3 polyunsaturated fatty acids promote amyloid-beta clearance from the brain through mediating the function of the glymphatic system","volume":"31","author":"Ren","year":"2017","journal-title":"FASEB J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/CIA.S5231","article-title":"Omega-3 fatty acids: Potential role in the management of early Alzheimer\u2019s disease","volume":"5","author":"Jicha","year":"2010","journal-title":"Clin. Interv. Aging"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Kope\u0107, K., Szleszkowski, S., Koziorowski, D., and Szlufik, S. (2023). Glymphatic System and Mitochondrial Dysfunction as Two Crucial Players in Pathophysiology of Neurodegenerative Disorders. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210366"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Yi, T., Gao, P., Zhu, T., Yin, H., and Jin, S. (2022). Glymphatic System Dysfunction: A Novel Mediator of Sleep Disorders and Headaches. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.885020"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"111899","DOI":"10.1016\/j.mad.2023.111899","article-title":"Sleep disorders and Alzheimer\u2019s disease pathophysiology: The role of the Glymphatic System. A scoping review","volume":"217","author":"Astara","year":"2023","journal-title":"Mech. Ageing Dev."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"eaau6550","DOI":"10.1126\/scitranslmed.aau6550","article-title":"Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer\u2019s disease","volume":"11","author":"Lucey","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Turton, S.M., Padgett, S., Maisel, M.T., Johnson, C.E., Buzinova, V.A., Barth, S.E., Kohler, K., Spearman, H.M., Macheda, T., and Manauis, E.C. (2025). Interactions between daily sleep-wake rhythms, gamma-secretase, and amyloid-beta peptide pathology point to complex underlying relationships. Biochim. Biophys. Acta Mol. Basis. Dis., 1871.","DOI":"10.1016\/j.bbadis.2025.167840"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Huang, H., Li, M., Zhang, M., Qiu, J., Cheng, H., Mou, X., Chen, Q., Li, T., Peng, J., and Li, B. (2021). Sleep Quality Improvement Enhances Neuropsychological Recovery and Reduces Blood A\u03b242\/40 Ratio in Patients with Mild\u2013Moderate Cognitive Impairment. Medicina, 57.","DOI":"10.3390\/medicina57121366"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrneurol.2013.269","article-title":"Sleep and Alzheimer disease pathology\u2014A bidirectional relationship","volume":"10","author":"Ju","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12603-010-0050-9","article-title":"Non-pharmacologic management of sleep disturbance in Alzheimer\u2019s disease","volume":"14","author":"David","year":"2010","journal-title":"J. Nutr. Health Aging"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14737175.2023.2214316","article-title":"Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer\u2019s disease","volume":"23","author":"Javed","year":"2023","journal-title":"Expert Rev. Neurother."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e2417449","DOI":"10.1002\/advs.202417449","article-title":"Hybrid Electro-optical Stimulation Improves Ischemic Brain Damage by Augmenting the Glymphatic System","volume":"12","author":"Kim","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Salehpour, F., Khademi, M., Bragin, D.E., and DiDuro, J.O. (2022). Photobiomodulation Therapy and the Glymphatic System: Promising Applications for Augmenting the Brain Lymphatic Drainage System. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23062975"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"474","DOI":"10.4103\/1673-5374.350191","article-title":"Lights at night: Does photobiomodulation improve sleep?","volume":"18","author":"Valverde","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Semyachkina-Glushkovskaya, O., Penzel, T., Blokhina, I., Khorovodov, A., Fedosov, I., Yu, T., Karandin, G., Evsukova, A., Elovenko, D., and Adushkina, V. (2021). Night Photostimulation of Clearance of Beta-Amyloid from Mouse Brain: New Strategies in Preventing Alzheimer\u2019s Disease. Cells, 10.","DOI":"10.3390\/cells10123289"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"101","DOI":"10.31887\/DCNS.2003.5.1\/hhippius","article-title":"The discovery of Alzheimer\u2019s disease","volume":"5","author":"Hippius","year":"2003","journal-title":"Dialogues Clin. Neurosci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/15\/7552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:23:22Z","timestamp":1760034202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/15\/7552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":168,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26157552"],"URL":"https:\/\/doi.org\/10.3390\/ijms26157552","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]}}}